BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

143 related articles for article (PubMed ID: 34167917)

  • 1. PI3K/Akt/mTOR signaling orchestrates the phenotypic transition and chemo-resistance of small cell lung cancer.
    Li X; Li C; Guo C; Zhao Q; Cao J; Huang HY; Yue M; Xue Y; Jin Y; Hu L; Ji H
    J Genet Genomics; 2021 Jul; 48(7):640-651. PubMed ID: 34167917
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Activation of PI3K/AKT Pathway Is a Potential Mechanism of Treatment Resistance in Small Cell Lung Cancer.
    Jin Y; Chen Y; Tang H; Hu X; Hubert SM; Li Q; Su D; Xu H; Fan Y; Yu X; Chen Q; Liu J; Hong W; Xu Y; Deng H; Zhu D; Li P; Gong Y; Xia X; Gay CM; Zhang J; Chen M
    Clin Cancer Res; 2022 Feb; 28(3):526-539. PubMed ID: 34921019
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Inhibition of the phosphatidylinositol 3-kinase/Akt/mammalian target of rapamycin pathway but not the MEK/ERK pathway attenuates laminin-mediated small cell lung cancer cellular survival and resistance to imatinib mesylate or chemotherapy.
    Tsurutani J; West KA; Sayyah J; Gills JJ; Dennis PA
    Cancer Res; 2005 Sep; 65(18):8423-32. PubMed ID: 16166321
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Progression and metastasis of small cell lung carcinoma: the role of the PI3K/Akt/mTOR pathway and metabolic alterations.
    Krencz I; Sztankovics D; Danko T; Sebestyen A; Khoor A
    Cancer Metastasis Rev; 2021 Dec; 40(4):1141-1157. PubMed ID: 34958428
    [TBL] [Abstract][Full Text] [Related]  

  • 5. PI3K/AKT/mTOR pathway, hypoxia, and glucose metabolism: Potential targets to overcome radioresistance in small cell lung cancer.
    Deng H; Chen Y; Li P; Hang Q; Zhang P; Jin Y; Chen M
    Cancer Pathog Ther; 2023 Jan; 1(1):56-66. PubMed ID: 38328610
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Activation of endoplasmic reticulum stress promotes autophagy and apoptosis and reverses chemoresistance of human small cell lung cancer cells by inhibiting the PI3K/AKT/mTOR signaling pathway.
    Yu XS; Du J; Fan YJ; Liu FJ; Cao LL; Liang N; Xu DG; Zhang JD
    Oncotarget; 2016 Nov; 7(47):76827-76839. PubMed ID: 27765907
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Activation of the PI3K/mTOR Pathway following PARP Inhibition in Small Cell Lung Cancer.
    Cardnell RJ; Feng Y; Mukherjee S; Diao L; Tong P; Stewart CA; Masrorpour F; Fan Y; Nilsson M; Shen Y; Heymach JV; Wang J; Byers LA
    PLoS One; 2016; 11(4):e0152584. PubMed ID: 27055253
    [TBL] [Abstract][Full Text] [Related]  

  • 8. AKT phosphorylation as a predictive biomarker for PI3K/mTOR dual inhibition-induced proteolytic cleavage of mTOR companion proteins in small cell lung cancer.
    Hung MC; Wang WP; Chi YH
    Cell Biosci; 2022 Aug; 12(1):122. PubMed ID: 35918763
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Metabolic Determinants of Sensitivity to Phosphatidylinositol 3-Kinase Pathway Inhibitor in Small-Cell Lung Carcinoma.
    Makinoshima H; Umemura S; Suzuki A; Nakanishi H; Maruyama A; Udagawa H; Mimaki S; Matsumoto S; Niho S; Ishii G; Tsuboi M; Ochiai A; Esumi H; Sasaki T; Goto K; Tsuchihara K
    Cancer Res; 2018 May; 78(9):2179-2190. PubMed ID: 29490947
    [TBL] [Abstract][Full Text] [Related]  

  • 10. FGFRL1 affects chemoresistance of small-cell lung cancer by modulating the PI3K/Akt pathway via ENO1.
    Chen R; Li D; Zheng M; Chen B; Wei T; Wang Y; Li M; Huang W; Tong Q; Wang Q; Zhu Y; Fang W; Guo L; Fang S
    J Cell Mol Med; 2020 Feb; 24(3):2123-2134. PubMed ID: 31957179
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Inhibition of phosphatidylinositol 3-kinase-Akt signaling blocks growth, promotes apoptosis, and enhances sensitivity of small cell lung cancer cells to chemotherapy.
    Krystal GW; Sulanke G; Litz J
    Mol Cancer Ther; 2002 Sep; 1(11):913-22. PubMed ID: 12481412
    [TBL] [Abstract][Full Text] [Related]  

  • 12. In vitro chemo- and radio-resistance in small cell lung cancer correlates with cell adhesion and constitutive activation of AKT and MAP kinase pathways.
    Kraus AC; Ferber I; Bachmann SO; Specht H; Wimmel A; Gross MW; Schlegel J; Suske G; Schuermann M
    Oncogene; 2002 Dec; 21(57):8683-95. PubMed ID: 12483521
    [TBL] [Abstract][Full Text] [Related]  

  • 13. MicroRNA-Related Polymorphisms in PI3K/Akt/mTOR Pathway Genes Are Predictive of Limited-Disease Small Cell Lung Cancer Treatment Outcomes.
    Jiang W; Zhang W; Wu L; Liu L; Men Y; Wang J; Liang J; Hui Z; Zhou Z; Bi N; Wang L
    Biomed Res Int; 2017; 2017():6501385. PubMed ID: 28280736
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Genetic profiling-based prognostic prediction of patients with advanced small-cell lung cancer in large scale analysis.
    Udagawa H; Umemura S; Murakami I; Mimaki S; Makinoshima H; Ishii G; Miyoshi T; Kirita K; Matsumoto S; Yoh K; Niho S; Tsuchihara K; Goto K
    Lung Cancer; 2018 Dec; 126():182-188. PubMed ID: 30527185
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Tumor cell heterogeneity in Small Cell Lung Cancer (SCLC): phenotypical and functional differences associated with Epithelial-Mesenchymal Transition (EMT) and DNA methylation changes.
    Krohn A; Ahrens T; Yalcin A; Plönes T; Wehrle J; Taromi S; Wollner S; Follo M; Brabletz T; Mani SA; Claus R; Hackanson B; Burger M
    PLoS One; 2014; 9(6):e100249. PubMed ID: 24959847
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Therapeutic priority of the PI3K/AKT/mTOR pathway in small cell lung cancers as revealed by a comprehensive genomic analysis.
    Umemura S; Mimaki S; Makinoshima H; Tada S; Ishii G; Ohmatsu H; Niho S; Yoh K; Matsumoto S; Takahashi A; Morise M; Nakamura Y; Ochiai A; Nagai K; Iwakawa R; Kohno T; Yokota J; Ohe Y; Esumi H; Tsuchihara K; Goto K
    J Thorac Oncol; 2014 Sep; 9(9):1324-31. PubMed ID: 25122428
    [TBL] [Abstract][Full Text] [Related]  

  • 17. EPHA3 regulates the multidrug resistance of small cell lung cancer via the PI3K/BMX/STAT3 signaling pathway.
    Peng J; Wang Q; Liu H; Ye M; Wu X; Guo L
    Tumour Biol; 2016 Sep; 37(9):11959-11971. PubMed ID: 27101199
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The insulin-like growth factor-I receptor kinase inhibitor, NVP-ADW742, sensitizes small cell lung cancer cell lines to the effects of chemotherapy.
    Warshamana-Greene GS; Litz J; Buchdunger E; García-Echeverría C; Hofmann F; Krystal GW
    Clin Cancer Res; 2005 Feb; 11(4):1563-71. PubMed ID: 15746061
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Inhibition of PI3K/Akt/mTOR signaling pathway alleviates ovarian cancer chemoresistance through reversing epithelial-mesenchymal transition and decreasing cancer stem cell marker expression.
    Deng J; Bai X; Feng X; Ni J; Beretov J; Graham P; Li Y
    BMC Cancer; 2019 Jun; 19(1):618. PubMed ID: 31234823
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Targeting the phosphatidylinositol 3-kinase (PI3K)/AKT/mammalian target of rapamycin (mTOR) pathway: an emerging treatment strategy for squamous cell lung carcinoma.
    Beck JT; Ismail A; Tolomeo C
    Cancer Treat Rev; 2014 Sep; 40(8):980-9. PubMed ID: 25037117
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.